*Organization & Developments: AbbVie (Archives 2017-2018)

Parents

2017: A Double Beat For AbbVie - AbbVie Inc. (NYSE:ABBV)
2017: AbbVie Declines After Humira Patent Loss - AbbVie Inc. (NYSE:ABBV)
2017: AbbVie, Part 2: Its Strengths Beyond Humira, And Weakness - AbbVie Inc. (NYSE:ABBV)
2018: ABBV Is An Even Bigger Buy After The Midterms_seekingalpha.com
2018: ABBVIE_Biotech Giant Should Deliver Mid-Teens Total Returnsseekingalpha.com
2018: AbbVie: Remarkable 700% Return Potential Over Next Decade (Dividend Sensei)
2018: AbbVie: Too Darn Hot? - AbbVie Inc. (NYSE:ABBV)
2018: AbbVie's Q1: It May Be Biotech's Apple, Circa 2005 - AbbVie Inc. (NYSE:ABBV)
2018: Buying The Latest AbbVie Sell-Off With Vigor - AbbVie Inc. (NYSE:ABBV)
2018: Street Fighting Man: Buying More AbbVie_seekingalpha.com
2018: Voyager Therapeutics inks deal with AbbVie to develop anti-tau antibodies in neurodegenerative diseases_seekingalpha.com
2018: Voyager Therapeutics Stock Rises On AbbVie Deal In Alzheimer's Disease